Alfredo Falcone Selected Research

Colorectal Neoplasms (Colorectal Cancer)

1/2022	Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
1/2022	Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives.
12/2021	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
10/2021	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
6/2021	Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
3/2021	PNN and KCNQ1OT1 Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients.
1/2021	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
1/2021	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
1/2021	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
1/2021	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alfredo Falcone Research Topics

Disease

143	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 04/2002
70	Neoplasms (Cancer) 03/2022 - 12/2002
28	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2006
17	Disease Progression 10/2021 - 03/2008
14	Pancreatic Neoplasms (Pancreatic Cancer) 06/2020 - 01/2008
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2022 - 05/2006
11	Adenocarcinoma 03/2022 - 06/2010
9	Stomach Neoplasms (Stomach Cancer) 03/2021 - 02/2004
9	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 08/2009
8	Breast Neoplasms (Breast Cancer) 03/2022 - 08/2009
8	Neutropenia 06/2021 - 03/2008
6	Rectal Neoplasms (Rectal Cancer) 07/2020 - 05/2014
6	Hypertension (High Blood Pressure) 12/2019 - 08/2009
5	Diarrhea 08/2020 - 03/2004
5	Colonic Neoplasms (Colon Cancer) 01/2020 - 01/2018
5	Fatigue 12/2019 - 03/2007
4	Biliary Tract Neoplasms (Biliary Tract Cancer) 10/2020 - 01/2011
4	Melanoma (Melanoma, Malignant) 02/2020 - 01/2017
3	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 02/2021 - 10/2006
3	Microsatellite Instability 01/2021 - 01/2018
3	Hepatocellular Carcinoma (Hepatoma) 12/2020 - 02/2014
3	Febrile Neutropenia 08/2020 - 09/2010
2	Carcinogenesis 03/2022 - 03/2012
2	Anemia 06/2021 - 01/2009
2	Carcinoma (Carcinomatosis) 02/2020 - 01/2019
2	Drug-Related Side Effects and Adverse Reactions 12/2019 - 10/2006
2	Inflammation (Inflammations) 01/2019 - 10/2015
2	Vomiting 01/2017 - 01/2009

Drug/Important Bio-Agent (IBA)

46	Bevacizumab (Avastin)FDA Link 03/2022 - 05/2007
42	Irinotecan (Camptosar)FDA LinkGeneric 11/2020 - 04/2002
35	Fluorouracil (Carac)FDA LinkGeneric 02/2021 - 10/2002
30	Cetuximab (Erbitux)FDA Link 01/2022 - 09/2007
28	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 10/2002
26	ErbB Receptors (EGF Receptor)IBA 01/2022 - 09/2007
25	Biomarkers (Surrogate Marker)IBA 02/2021 - 03/2010
21	Leucovorin (Folinic Acid)FDA Link 07/2020 - 10/2002
16	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2022 - 05/2007
16	Monoclonal AntibodiesIBA 01/2022 - 01/2008
14	Gemcitabine FDA Link 01/2020 - 01/2008
13	regorafenibIBA 12/2021 - 01/2013
10	trifluridine tipiracil drug combinationIBA 06/2021 - 01/2015
10	Pharmaceutical PreparationsIBA 06/2021 - 12/2002
9	Panitumumab (Vectibix)FDA Link 01/2022 - 12/2008
9	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 08/2009
8	Proteins (Proteins, Gene)FDA Link 03/2021 - 04/2007
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2021 - 08/2009
7	Immune Checkpoint InhibitorsIBA 09/2021 - 01/2018
7	folfirinoxIBA 01/2020 - 01/2016
7	Capecitabine (Xeloda)FDA Link 01/2020 - 09/2006
6	AntibodiesIBA 09/2021 - 07/2015
6	Cisplatin (Platino)FDA LinkGeneric 08/2010 - 02/2004
5	Paclitaxel (Taxol)FDA LinkGeneric 03/2022 - 08/2009
5	Tyrosine Kinase InhibitorsIBA 10/2020 - 08/2008
5	MicroRNAs (MicroRNA)IBA 06/2020 - 01/2012
5	Docetaxel (Taxotere)FDA Link 12/2014 - 05/2006
4	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 03/2022 - 12/2014
4	PlatinumIBA 01/2022 - 12/2009
4	Formaldehyde (Formol)FDA Link 03/2021 - 12/2008
4	Messenger RNA (mRNA)IBA 03/2021 - 04/2013
4	ParaffinIBA 03/2021 - 03/2010
4	Sorafenib (BAY 43-9006)FDA Link 12/2020 - 02/2013
4	130-nm albumin-bound paclitaxelIBA 01/2020 - 01/2016
4	Biological ProductsIBA 01/2020 - 11/2009
4	thiamine triphosphorate (TTP)IBA 06/2013 - 09/2006
3	Calcibiotic Root Canal SealerIBA 01/2022 - 07/2015
3	Celecoxib (Celebrex)FDA Link 02/2021 - 08/2009
3	Epidermal Growth Factor (EGF)IBA 01/2021 - 09/2019
3	Hormones (Hormone)IBA 01/2020 - 08/2009
3	Circulating Tumor DNAIBA 12/2019 - 07/2015
3	Antineoplastic Agents (Antineoplastics)IBA 01/2018 - 09/2007
3	RNA (Ribonucleic Acid)IBA 01/2018 - 01/2012
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2017 - 05/2006
3	Gefitinib (Iressa)FDA Link 02/2011 - 08/2008
2	GoldIBA 03/2022 - 11/2021
2	Thrombospondin 1IBA 03/2022 - 12/2014
2	Interleukin-8 (Interleukin 8)IBA 03/2022 - 12/2014
2	InterferonsIBA 01/2022 - 02/2013
2	atezolizumabIBA 07/2020 - 01/2019
2	LigandsIBA 02/2020 - 09/2014
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 02/2018
2	NivolumabIBA 01/2020 - 01/2020
2	Ifosfamide FDA LinkGeneric 01/2020 - 05/2006
2	Epirubicin (Ellence)FDA LinkGeneric 01/2020 - 02/2004
2	EnzymesIBA 12/2019 - 04/2013
2	Codon (Codons)IBA 12/2019 - 12/2008
2	Angiogenesis InhibitorsIBA 01/2019 - 08/2013
2	AlbuminsIBA 08/2018 - 01/2018
2	Androgen Receptors (Androgen Receptor)IBA 01/2018 - 01/2017
2	NucleosidesIBA 01/2018 - 01/2011
2	liposomal doxorubicin (Doxil)FDA Link 02/2017 - 11/2009
2	Insulin-Like PeptidesIBA 01/2017 - 10/2010
2	MitogensIBA 01/2017 - 02/2009

Therapy/Procedure

64	Drug Therapy (Chemotherapy) 01/2022 - 10/2002
53	Therapeutics 01/2022 - 09/2007
8	Adjuvant Chemotherapy 11/2021 - 12/2002
6	Immunotherapy 04/2022 - 05/2009
5	Castration 01/2017 - 05/2010
2	Heterologous Transplantation (Xenotransplantation) 08/2021 - 06/2020
2	Neoadjuvant Therapy 01/2020 - 01/2019
2	Chemoradiotherapy 01/2019 - 12/2015